| Randolph Thomas Jackson, MD | |
|
11010 Haskell Ave, Kansas City, KS 66109-8500 | |
| (816) 478-1230 | |
| (816) 350-4166 |
| Full Name | Randolph Thomas Jackson |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 24 Years |
| Location | 11010 Haskell Ave, Kansas City, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457310518 | NPI | - | NPPES |
| P00685107 | Other | KS | RAILROAD MEDICARE |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Eye Care Llc | 4385544600 | 36 |
| Eye Care Llc | 4385544600 | 36 |
News Archive
A team of scientists at Florida Atlantic University has uncovered a brain-signaling pathway that can be pharmacologically manipulated in genetically engineered mice to reverse an autism-related pathway.
Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.
The U.S. Food and Drug Administration today alerted consumers, health care providers and other users of thermal imaging systems intended to measure human body temperature—also known as telethermographic systems, infrared thermographs, thermal cameras, and "fever cameras"—that improper use of the systems may provide inaccurate temperature readings due to a variety of factors.
Cancer Research Technology (CRT) and The Institute of Cancer Research (ICR) today announced a major research collaboration with AstraZeneca. The three partners will combine their expertise to discover and develop potential new anti-cancer drugs to target molecular "chaperones" which support the growth of cancer cells.
With the publication of the nation's first comprehensive, federally funded guide to hospital emergency preparedness exercise development, Dr. Nathaniel Hupert at Weill Cornell Medical College and his collaborators have provided a new toolset for strengthening hospitals' ability to protect communities nationwide against public health disasters, such as creating care centers during an influenza pandemic or treating casualties in the wake of a bioterrorism attack.
› Verified 9 days ago
| Entity Name | Eye Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609066034 PECOS PAC ID: 4385544600 Enrollment ID: O20040204000494 |
News Archive
A team of scientists at Florida Atlantic University has uncovered a brain-signaling pathway that can be pharmacologically manipulated in genetically engineered mice to reverse an autism-related pathway.
Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.
The U.S. Food and Drug Administration today alerted consumers, health care providers and other users of thermal imaging systems intended to measure human body temperature—also known as telethermographic systems, infrared thermographs, thermal cameras, and "fever cameras"—that improper use of the systems may provide inaccurate temperature readings due to a variety of factors.
Cancer Research Technology (CRT) and The Institute of Cancer Research (ICR) today announced a major research collaboration with AstraZeneca. The three partners will combine their expertise to discover and develop potential new anti-cancer drugs to target molecular "chaperones" which support the growth of cancer cells.
With the publication of the nation's first comprehensive, federally funded guide to hospital emergency preparedness exercise development, Dr. Nathaniel Hupert at Weill Cornell Medical College and his collaborators have provided a new toolset for strengthening hospitals' ability to protect communities nationwide against public health disasters, such as creating care centers during an influenza pandemic or treating casualties in the wake of a bioterrorism attack.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Randolph Thomas Jackson, MD 4801 S Cliff Ave, Suite 100, Independence, MO 64055-7015 Ph: (816) 350-4536 | Randolph Thomas Jackson, MD 11010 Haskell Ave, Kansas City, KS 66109-8500 Ph: (816) 478-1230 |
News Archive
A team of scientists at Florida Atlantic University has uncovered a brain-signaling pathway that can be pharmacologically manipulated in genetically engineered mice to reverse an autism-related pathway.
Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.
The U.S. Food and Drug Administration today alerted consumers, health care providers and other users of thermal imaging systems intended to measure human body temperature—also known as telethermographic systems, infrared thermographs, thermal cameras, and "fever cameras"—that improper use of the systems may provide inaccurate temperature readings due to a variety of factors.
Cancer Research Technology (CRT) and The Institute of Cancer Research (ICR) today announced a major research collaboration with AstraZeneca. The three partners will combine their expertise to discover and develop potential new anti-cancer drugs to target molecular "chaperones" which support the growth of cancer cells.
With the publication of the nation's first comprehensive, federally funded guide to hospital emergency preparedness exercise development, Dr. Nathaniel Hupert at Weill Cornell Medical College and his collaborators have provided a new toolset for strengthening hospitals' ability to protect communities nationwide against public health disasters, such as creating care centers during an influenza pandemic or treating casualties in the wake of a bioterrorism attack.
› Verified 9 days ago
Martin A Mainster, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 3901 Rainbow Blvd, Kansas City, KS 66160 Phone: 913-588-6605 Fax: 913-588-0888 | |
Dr. Neeti Alapati, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 4000 Cambridge St, Kansas City, KS 66160 Phone: 913-588-6600 Fax: 913-588-6651 | |
Karl D Hendricks, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 8919 Parallel Pkwy, Ste 226, Kansas City, KS 66112 Phone: 913-299-8800 Fax: 913-299-6581 | |
Dr. Anne Berenbom Wishna, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 4000 Cambridge St, Kansas City, KS 66160 Phone: 913-588-1227 | |
Gurinder Singh, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 155 South 18th Street, Suite 220, Kansas City, KS 66102 Phone: 913-321-7327 Fax: 913-321-3168 | |
Hasan Bahrani, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 3901 Rainbow Blvd, Ms 3009, Kansas City, KS 66160 Phone: 913-588-6660 |